BTIG Research Cuts Tvardi Therapeutics (NASDAQ:TVRD) Price Target to $15.00

Tvardi Therapeutics (NASDAQ:TVRD) had its price target trimmed by BTIG Research from $55.00 to $15.00 in a research report sent to investors on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts also recently issued reports on TVRD. Barclays started coverage on Tvardi Therapeutics in a research report on Monday. They set an “overweight” rating and a $61.00 price target on the stock. Piper Sandler downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday. Raymond James Financial initiated coverage on Tvardi Therapeutics in a research report on Monday, July 14th. They set an “outperform” rating and a $62.00 price target on the stock. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Saturday, September 27th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tvardi Therapeutics has an average rating of “Hold” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Down 5.1%

Tvardi Therapeutics stock opened at $6.64 on Monday. The business’s fifty day moving average is $30.90. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

Institutional Investors Weigh In On Tvardi Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth about $43,000. Headlands Technologies LLC acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth about $80,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth about $92,000. Finally, Bank of America Corp DE acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth about $399,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.